| HOME >> MEDICINE >> TECHNOLOGY |
(9) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [abstract]. Blood. 2006;108(11):290a. Abstract 985.
(10) Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996; 348:573-577.
(11) Hillmen P. Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253-1258.
(12) Hill A, Richards S, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 2007; 137:3, 181-
-
192.
(13) Soliris(TM) (eculizumab) prescribing information. Alexion Pharmaceuticals, Inc., 2006.
CONTACT: Leonard Bell, M.D., Chief Executive Officer of AlexionPharmaceuticals, Inc., +1-203-272-2596, Media, David Patti, Makovsky +Company, +1-212-508-9623, , or Investors, Rhonda Chigerof Rx Communications Group, LLC, +1-917-322-2569, or dpatti@makovsky.com rchiger@rxir.com
Web site: http://www.soliris.net/http://www.alexionpharm.com/
Ticker Symbol: (NASDAQ-NMS:ALXN)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company